Avatar
Leek8layer

0 Following 0 Followers
5
Our prior studies using HTh74 cells in the orthotopic murine thyroid cancer model system, we have observed that the in vivo growth rates are slower compared to other thyroid cancer cell lines (84 days to achieve 100 mm3 tumors compared with 28?5 days in other ATC cell lines). It is possible that if our study had been temporally extended, the trend in tumor volume attenuation in the TXNIP-overexpre
4
Our prior studies using HTh74 cells in the orthotopic murine thyroid cancer model system, we have observed that the in vivo growth rates are slower compared to other thyroid cancer cell lines (84 days to achieve 100 mm3 tumors compared with 28?5 days in other ATC cell lines). It is possible that if our study had been temporally extended, the trend in tumor volume attenuation in the TXNIP-overexpre
4
Ated development of high grade and invasive tumors by 4 weeks compared to controlswith wild-type expression, however, controls eventually succumb to tumor development and TXNIP expression in these tumors has been downregulated by other mechanisms [24]. In the orthotopic ATC model, TXNIP overexpression also led to a significant reduction in pulmonary metastatic burden. Inhibition of metastasis con
3
Our prior studies using HTh74 cells in the orthotopic murine thyroid cancer model system, we have observed that the in vivo growth rates are slower compared to other thyroid cancer cell lines (84 days to achieve 100 mm3 tumors compared with 28?5 days in other ATC cell lines). It is possible that if our study had been temporally extended, the trend in tumor volume attenuation in the TXNIP-overexpre
1
Promoting a pro-apoptotic environment [13,15-20]. Independent of its interaction with thioredoxin, TXNIP also has the ability to inhibit cell cycle progression by indirectly stabilizing the cell cycle inhibitor p27Kip1 [9]. In addition, TXNIPMorrison et al. Molecular Cancer 2014, 13:62 http://www.molecular-cancer.com/content/13/1/Page 8 ofAvectorB*** *TXNIPCD******Figure 5 TXNIP overexpression in
1
Uares () indicate vector control cells, and open diamonds () indicate cells with TXNIP overexpression. In vitro invasion assays were performed on the TXNIP-overexpressing stable HTh74 (C) and T238 (D) cell lines as described in the Methods section. Results from three independent experiments were combined and normalized to the vector control average and graphed with mean plus SEM. *p
1
Gnosis and increased mortality [49,50]. The mechanism underlying this differential glucose uptake between well-differentiated PTC and ATC is not well understood. The novel finding that TXNIP expression is low in ATC is consistent with the observed FDG uptake on PET/CT in patients with ATC, supporting a critical role for TXNIP as a metabolic regulator in thyroid cancer progression. In addition to i
1
Gnosis and increased mortality [49,50]. The mechanism underlying this differential glucose uptake between well-differentiated PTC and ATC is not well understood. The novel finding that TXNIP expression is low in ATC is consistent with the observed FDG uptake on PET/CT in patients with ATC, supporting a critical role for TXNIP as a metabolic regulator in thyroid cancer progression. In addition to i
1
Promoting a pro-apoptotic environment [13,15-20]. Independent of its interaction with thioredoxin, TXNIP also has the ability to inhibit cell cycle progression by indirectly stabilizing the cell cycle inhibitor p27Kip1 [9]. In addition, TXNIPMorrison et al. Molecular Cancer 2014, 13:62 http://www.molecular-cancer.com/content/13/1/Page 8 ofAvectorB*** *TXNIPCD******Figure 5 TXNIP overexpression in
1
R model and IV tail injection metastasis model relative to vector controls [27]. In human breast cancer, high TXNIP levels are associated with longer metastasis-free intervals and better prognosis than those with low TXNIP expression [43,46]. These data implicate TXNIP as a tumor suppressor in a variety of cancers and, for the first time, is now shown to be a tumor suppressor in thyroid cells. Cur
1
Gnosis and increased mortality [49,50]. The mechanism underlying this differential glucose uptake between well-differentiated PTC and ATC is not well understood. The novel finding that TXNIP expression is low in ATC is consistent with the observed FDG uptake on PET/CT in patients with ATC, supporting a critical role for TXNIP as a metabolic regulator in thyroid cancer progression. In addition to i
1
Oscope to enhance visualization. Weekly imaging with IVIS after injection of luciferin was performed to monitor tumor establishment and growth. There were 10?1 mice per group in each experiment, and the experiment was performed two times. (A) Representative images of one mouse per group imaged by IVIS over time are shown. (B) Quantitation of the bioluminescence from one experiment is shown with av